Glucose infusion arrests the decompensatory phase of hemorrhagic shock.
Waning of hyperglycemia has been shown to be closely associated with the deterioration of mechanisms supporting homeostasis during hemorrhagic shock. However, the mechanisms which link plasma glucose levels to maintenance of homeostasis during hemorrhagic shock are not clear. The goal of the present study was to evaluate the importance of glucose to maintenance of compensatory mechanisms. This was undertaken by maintaining plasma glucose levels through infusion of hypertonic glucose (2-3 M) starting at the onset of decompensation during persisting hypovolemia. Administration of glucose at a rate of between 60 and 80 mumoles/min X kg arrested the fall in glucose concentration and significantly slowed or arrested the decompensatory phase. All of the saline infused control animals (n = 6) died within 3 hours after reaching their maximum shed blood volume, averaging 145 +/- 25 minutes, while two of the eight animals in the glucose infusion group died less than 4 hours after reaching the maximum shed blood volume. The remaining six animals were sacrificed between 270 and 397 minutes (average, 340 +/- 22 minutes) after reaching the maximum shed blood volume since decompensation was arrested. Compared to the saline-infused control group, animals receiving glucose infusion exhibited a more moderate acidosis, and the hemoconcentration which normally accompanies decompensation was also prevented. Since the increase in plasma osmolality and the fraction of the total osmolality change accounted for by glucose was less in the glucose-infused animals, these results suggest that the effect is not mediated through a glucose-related maintenance of a transcapillary osmotic gradient.(ABSTRACT TRUNCATED AT 250 WORDS)
Pearce
F J
FJ
Department of Surgery, University of Rochester School of Medicine and Dentistry, NY 14642.
Drucker
W R
WR
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D004734:Energy Metabolism; D005110:Extracellular Space / Q000378:metabolism; D005947:Glucose / Q000627:therapeutic use*; D005950:Glucose Solution, Hypertonic / Q000627:therapeutic use*; D006706:Homeostasis; D006943:Hyperglycemia / Q000209:etiology*; D008297:Male; D009994:Osmolar Concentration; D051381:Rats; D011919:Rats, Inbred Strains; D012771:Shock, Hemorrhagic / Q000150:complications / Q000628:therapy*
D001786:Blood Glucose; D005950:Glucose Solution, Hypertonic; D005947:Glucose